Daniel F. Heitjan

Daniel F. Heitjan

Auto-generated profile, based on publicly available information

Daniel F. Heitjan

Department of Statistics and Data Science, Southern Methodist University, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2011 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RRR. Reshef
R. Reshef
SVS. Vardhanabhuti
S. Vardhanabhuti
MLM. R. Luskin
M. R. Luskin
DHD. F. Heitjan
D. F. Heitjan
DHD. Hadjiliadis
D. Hadjiliadis
DTD. E. Tsai
D. E. Tsai
Reduction of immunosuppression (RI) is commonly used to treat posttransplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients. We investigated the efficacy, safety and predictors of response to RI in adult patients with PTLD. Sixty‐seven patients were managed with RI alone and 30 patients were treated with surgical excision followed by adjuvant RI. The response rate to RI alone was 45% (complete response—37%, partial response—8%). The relapse rate in complete responders was 17%. Adjuvant RI resulted in a 27% relapse rate. The acute rejection rate following RI‐containing strategies was 32% and a second transplant was feasible without relapse of PTLD. The median survival was 44 months in patients treated with RI alone and 9.5 months in patients who remained on full immunosuppression (p = 0.07). Bulky disease, advanced stage and older age predicted lack of response to RI. Survival analysis demonstrated predictors of poor outcome—age, dyspnea, B symptoms, LDH level, hepatitis C, bone marrow and liver involvement. Patients with none or one of these factors had a 3‐year overall survival of 100% and 79%, respectively. These findings support the use of RI alone in low‐risk PTLD and suggest factors that predict response and survival.

1 November 2015 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
DHDaniel F. Heitjan
Daniel F. Heitjan
ZGZhiyun Ge
Zhiyun Ge
GYGui-Shuang Ying
Gui-Shuang Ying

8 November 2018 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
YLYu Lan
Yu Lan
GTGong Tang
Gong Tang
DHDaniel F. Heitjan
Daniel F. Heitjan

13 February 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
RSRichard J Santen
Richard J Santen
DHDaniel F Heitjan
Daniel F Heitjan
AGAnne Gompel
Anne Gompel
MLMary Ann Lumsden
Mary Ann Lumsden
JPJoAnn V Pinkerton
JoAnn V Pinkerton
CSCynthia A Stuenkel
Cynthia A Stuenkel
The recent Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC) publication calculated the attributable risk of breast cancer from use of estrogen alone and estrogen plus a synthetic progestogen for <5 to ≥15 years of use. This CGHFB report calculated attributable risk based on their findings of relative risk from pooled data from 58 studies. Notably, neither the CGHFBC nor other previous studies have examined the effect of underlying risk of breast cancer on attributable risk. This omission prompted us to determine the magnitude of the effect of underlying risk on attributable risk in this Perspective. Meaningful communication of the potential risk of menopausal hormonal therapy requires providing women with the estimated risk above their existing underlying risk (i.e. attributable risk). Therefore we have estimated attributable risks from the data published by the CGHFBC, taking into account varying degrees of underlying risk. Based on the Endocrine Society Guideline on Menopausal Hormone Therapy (MHT), we divided groups into three categories of risk: low (1.5%), intermediate (3.0%), and high (6.0%) underlying risk of breast cancer over 5 years. In women taking estrogen plus a synthetic progestogen (E+SP) for 5–9 years, the attributable risks of MHT increased from 12, to 42, to 85 additional women per 1000 in the low, intermediate, and high risk groups respectively. The attributable risks for estrogen alone were lower but also increased based on underlying risk. Notably, the attributable risks were amplified with duration of MHT use which increased both relative risk and breast cancer incidence.

1 September 2013 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
RSRichard J. Santen
Richard J. Santen
YSYan Song
Yan Song
WYWei Yue
Wei Yue
JWJi-Ping Wang
Ji-Ping Wang
DHDaniel F. Heitjan
Daniel F. Heitjan

1 December 2012 in The Annals of Applied Statistics
Verified
Journal Article
Open access
PDF file
HWHao Wang
Hao Wang
Saul ShiffmanSaul Shiffman
Saul Shiffman
SGSandra D. Griffith
Sandra D. Griffith
DHDaniel F. Heitjan
Daniel F. Heitjan
Studies of smoking behavior commonly use the time-line follow-back (TLFB) method, or periodic retrospective recall, to gather data on daily cigarette consumption. TLFB is considered adequate for identifying periods of abstinence and lapse but not for measurement of daily cigarette consumption, thanks to substantial recall and digit preference biases. With the development of the hand-held electronic diary (ED), it has become possible to collect cigarette consumption data using ecological momentary assessment (EMA), or the instantaneous recording of each cigarette as it is smoked. EMA data, because they do not rely on retrospective recall, are thought to more accurately measure cigarette consumption. In this article we present an analysis of consumption data collected simultaneously by both methods from 236 active smokers in the pre-quit phase of a smoking cessation study. We define a statistical model that describes the genesis of the TLFB records as a two-stage process of mis-remembering and rounding, including fixed and random effects at each stage. We use Bayesian methods to estimate the model, and we evaluate its adequacy by studying histograms of imputed values of the latent remembered cigarette count. Our analysis suggests that both mis-remembering and heaping contribute substantially to the distortion of self-reported cigarette counts. Higher nicotine dependence, white ethnicity and male sex are associated with greater remembered smoking given the EMA count. The model is potentially useful in other applications where it is desirable to understand the process by which subjects remember and report true observations.